新设神经内分泌肿瘤专病肿瘤委员会的初步经验
回顾性分析2018年7月至2021年12月神经内分泌肿瘤(NEN)肿瘤委员会(TB)的652条推荐记录,记录患者特征、TB结局及其关联。影像审核占97.2%,最常用PET(55.3%)和CT(44.3%);20.8%的影像审核确定无疾病进展,36.1%的患者推荐了重大治疗改变。结论:NEN-TB高度依赖影像审核,可影响罕见肿瘤患者的重大治疗改变,转为虚拟形式未受影响。
要点
- NEN-TB讨论中97.2%的病例进行了影像审核,最常用PET(55.3%)和CT(44.3%)。
- 影像审核在20.8%的病例中确定无疾病进展,36.1%的患者推荐了重大治疗改变。
- 患者或疾病表现与TB结局无关联,转为虚拟形式后每场讨论患者数从10.0降至8.2(p < 0.001)。
核心结论
- NEN-TB高度依赖影像审核,可影响罕见肿瘤如NEN患者的重大治疗改变,转为虚拟形式未受影响,且所考察因素均不能预测TB推荐。
研究设计与样本
- 回顾性综述2018年7月至2021年12月所有NEN-TB推荐,共652条患者记录,记录患者特征、TB结局及其关联。
临床应用与阅片要点
- 影像审核是NEN-TB的核心环节(占97.2%),最常审核PET(55.3%)和CT(44.3%),影像审核在20.8%的病例中确定无疾病进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the decision patterns of a neuroendocrine neoplasm (NEN) tumor board (TB) and the factors behind those.
METHODS: We retrospectively reviewed all NEN-TB recommendations from 07/2018 to 12/2021 and recorded patient characteristics, TB outcomes and associations between them.
RESULTS: A total of 652 patient entries were identified. Median age of participants was 61 years and an equal number of men and women were presented. Most patients (33.4%) had tumors originating in the small bowel with 16.8% of high grade and 25.9% of pancreatic origin. Imaging was reviewed 97.2% of the time, with most frequently reviewed modalities being PET (55.3%) and CT (44.3%). Imaging review determined that there was no disease progression 20.8% of the time and significant treatment changes were recommended in 36.1% of patients. Major pathology amendments occurred in 3.7% of cases and a clinical trial was identified in 2.6%. There was no association between patient or disease presentation with the tumor board outcomes. There was a slight decrease in number of patients discussed per session, from 10.0 to 8.2 (p < 0.001) when the TB transitioned to a virtual format during the COVID-19 pandemic but all other factors remained unchanged.
CONCLUSION: NEN-TB relies heavily on image review, can impact significant treatment changes in patients with rare tumors like NENs, and was not affected by the switch to a virtual format. Finally, none of the examined factors were predictive of the tumor board recommendations.
引用
- Trikalinos NA, Hammill C, Liu J, et al. Preliminary experience with a new institutional tumor board dedicated to patients with neuroendocrine neoplasms. Abdom Radiol (NY). 2022. PMID: 36266515. doi:10.1007/s00261-022-03707-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。